A guide to CAR T cell therapies: development, current status and future prospects.
Authoritative review synthesises CAR T engineering advances, approved uses, toxicity management, and emerging strategies to extend effectiveness beyond blood cancers.
Rafei, Upadhyay, and Sharma provide an authoritative review of CAR T cell therapy in Nature Reviews Immunology, synthesising foundational engineering principles, FDA-approved indications across haematological malignancies, toxicity management approaches, and resistance mechanisms. The review covers next-generation CAR designs including co-stimulatory domain optimisation, armoured and dual-targeting strategies, and approaches to extend CAR T efficacy in solid tumours and overcome persistence barriers.
What the study was
- Study design
- Comprehensive authoritative narrative review (Nature Reviews)
- Population
- Haematological and solid tumour patients receiving CAR T cell therapy
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Nat Rev Immunol
Why it surfaced
Authoritative review in Nature Reviews Immunology; comprehensive translational roadmap for CAR T evolution directly relevant to novel therapeutics and hematologic malignancy topics.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.